Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navitoclax, Venetoclax, and Decitabine in Relapsed/Refractory High-Risk MDS
NCT05564650Phase 1Completed
- Sponsor
- Thomas Jefferson University
- Start
- Jan 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of navitoclax in myelodysplastic syndrome (MDS), sponsored by Thomas Jefferson University. Primary endpoints: Maximally Tolerated Dose of Navitoclax in Combination with Venetoclax and Decitabine at 30 days and Complete Response Rate at 4 months. Started Jan 2023; status: completed.
02
Drugs
navitoclax
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05564650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05564650.